Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 36-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Including a 2 Year Extension Study to Evaluate Efficacy and Safety of Aliskiren on the Prevention of Left Ventricular Remodeling in High Risk Post-acute Myocardial Infarction Patients When Added to Optimized Standard Therapy

Next Previous
X
Search
Trial Profile

A 36-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Including a 2 Year Extension Study to Evaluate Efficacy and Safety of Aliskiren on the Prevention of Left Ventricular Remodeling in High Risk Post-acute Myocardial Infarction Patients When Added to Optimized Standard Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Aug 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Cardiovascular disorders; Heart failure; Myocardial infarction
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASPIRE
  • Sponsors Novartis; Novartis Healthcare

    • Most Recent Events

    • 12 Jul 2012 Official Title amended as reported by ClinicalTrials.gov.
    • 23 Jun 2010 New source identified and integrated (Clinical Trials Registry - India record CTRI2009-091-000197).
    • 18 Mar 2010 Novartis, in a company media release, has said it does not intend to conduct an outcome trial for post-myocardial infarction patients, based on the results of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top